What Is Chikungunya?

Chikungunya is a mosquito-borne viral disease caused by chikungunya virus (CHIKV), an alphavirus transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The name means "that which bends up" in the Kimakonde language — a reference to the contorted posture caused by intense joint pain, the hallmark symptom of the disease. While chikungunya is rarely fatal (case fatality rate below 1% in most outbreaks), it causes debilitating arthralgia (joint pain) that persists for months to years in 30–40% of patients, creating significant economic and quality-of-life burden. In 2023, the FDA approved Ixchiq — the first chikungunya vaccine — for adults 18 and older.

Incubation: 2–12 days (typically 3–7 days). The disease has two phases:

Acute phase (days 1–7): Sudden high fever (39–40°C), severe polyarthralgia (joint pain in multiple joints, often bilateral and symmetric), arthritis (joint swelling), headache, muscle pain, rash (maculopapular, affecting trunk and limbs), fatigue
Post-acute/chronic phase: In 30–40% of patients, joint pain persists for months to years after the acute illness resolves. This chronic arthralgia is the most significant long-term burden of chikungunya and can be severe enough to cause disability.

There is no approved antiviral for chikungunya. Management is entirely symptomatic. Important: In areas where dengue co-circulates, avoid NSAIDs (ibuprofen, aspirin, naproxen) until dengue is excluded — dengue causes thrombocytopenia and NSAIDs increase bleeding risk. Once dengue is ruled out, NSAIDs are first-line for chikungunya's joint pain. Paracetamol, physiotherapy, and in persistent cases hydroxychloroquine (off-label) may help with chronic arthritis.

Ixchiq (Valneva, FDA-approved November 2023) is a live-attenuated chikungunya vaccine for adults 18+. A single dose provides protection. It is primarily recommended for travelers to endemic areas. A recombinant VLP vaccine (PXVX0317 by Bavarian Nordic) completed Phase 3 trials with strong efficacy and may receive approval in 2025–2026. Mosquito bite prevention: DEET repellent, long clothing, eliminating standing water breeding sites, window screens.

How is chikungunya different from dengue?: Both are spread by the same Aedes mosquitoes and co-circulate in the same regions, causing similar initial symptoms. Key differences: chikungunya causes more severe and longer-lasting joint pain; dengue is more likely to cause bleeding complications (thrombocytopenia) and is more often fatal when severe. Laboratory testing (PCR or serology) definitively distinguishes them. The treatment difference is critical: NSAIDs are contraindicated in dengue (bleeding risk) but are first-line for chikungunya once dengue is excluded.
Can chikungunya come back after recovery?: You cannot be re-infected with chikungunya after recovery — a single infection provides lifelong immunity (unlike dengue, where 4 serotypes allow repeat infections). However, the joint pain from an acute chikungunya infection can recur or persist for years after the original illness, especially in older patients and those with pre-existing arthritis. This is chronic post-chikungunya arthritis, not re-infection.
Is there a risk of chikungunya in Europe or the US?: Local mosquito-borne transmission has occurred in Europe — Italy (2007, 2017), France (2014, 2022) — and in the US (Florida, Texas, Caribbean territories) via imported cases seeding local Aedes albopictus mosquito populations. The risk is low but real, particularly in southern Europe and the southeastern US during warm months. The first FDA-approved chikungunya vaccine (Ixchiq) is specifically recommended for travelers to endemic regions.